Publication

Article

Evidence-Based Oncology

June 2024
Volume30
Issue 7

Chart Abstraction Pilot Improves Data Accuracy

Author(s):

Interview on Ontada research presented at ISPOR 2024.

Use of real-world data in research demands that data pulled from electronic health records are accurate. New research from Ontada shows how doing a pilot ahead of the main chart abstraction process can identify and correct potential error sources, thus ensuring high-quality data.

Sarah Spark, MHA, MBA | Image: Ontada

Sarah Spark, MHA, MBA | Image: Ontada

A poster presented May 7, 2024, at ISPOR—The Professional Society for Health Economics and Outcomes Research detailed the chart abstraction pilot. Sarah Spark, MHA, MBA, director, clinical data quality for Ontada, presented the findings and spoke with Evidence-Based Oncology about the results.
In a typical data-gathering process, Spark explained, chart abstractors pull individual data points for a given study, which can vary from how treatment was sequenced to whether patients were hospitalized. Then, a reviewer goes back through the data to ensure the chart abstraction is accurate.

The pilot process featured a 60-minute education session on the clinical variables to be pulled for the specific study, she said. Abstractors then pulled data from 2 charts each over a 2-week period and investigators calculated an accuracy rate: the number of correctly abstracted variables divided by the total number of variables observed. Abstractors received reeducation if they had an accuracy rate on an individual variable below 80% or if their overall accuracy rate was below 90%.

Abstractors then completed data abstraction on the remaining charts and this process was reviewed for accuracy. Investigators found that the mean accuracy rate for 15 studies during the pilot phase was 94.5%, while the mean fully study accuracy rate was 97.1%. This was “a statistically significant increase over the mean pilot accuracy rate (P = .046),” investigators wrote.

Previously, Spark said, “we didn’t necessarily always do the pilot.” “But what we learned from doing the pilot and getting the metrics is that we can then reeducate specific chart abstractors on specific variables.”

Variables that required reeducation included clinical characteristics and treatment history, they wrote. The need for the pilot process becomes clear, Spark said, as more research involves unstructured data, which calls for abstractors to look deep into the charts for the right data.

Results from this new analysis demonstrate the value of the pilot. “It increases the quality,” Spark said. “Instead of just giving someone 500 charts and saying. ‘Good luck,’ you’re saying, ‘You need to do these 2 charts, [and] I’m going to do source data verification or [quality control] on them. And now they have the opportunity to say, ‘Yes, now I’ve learned. Now I know how to extract it.’”

Reference


Reinwald S, DiIullo S, Fonseca L, et al. Implementing a pilot chart abstraction period improves the overall accuracy rate in chart abstraction. Value Health. 2024;27(6):S1,RWD111.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo